Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radionuclide olaratumab conjugate - Telix Pharmaceuticals

Next Previous
Drug Profile

Radionuclide olaratumab conjugate - Telix Pharmaceuticals

Alternative Names: 89Zr-olaratumab; 89Zr-TLX300-CDx; TLX-300; TLX-300-CDx

Latest Information Update: 31 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Telix Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Soft tissue sarcoma

Most Recent Events

  • 16 Dec 2024 Phase-I clinical trials in Soft tissue sarcoma (Diagnosis) in Australia (unspecified route) (NCT06537596)
  • 05 Aug 2024 Telix Pharmaceuticals plans a phase I ZOLAR trial for Soft tissue sarcoma (Diagnosis) in Australia (injection) in August 2024 (NCT06537596)
  • 11 Apr 2024 Phase-I clinical trials in Soft tissue sarcoma (Diagnosis) (unspecified route) (Telix Pharmaceuticals pipeline, April 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top